Department of Neurosciences and Rehabilitation, Tampere University Hospital, P.O. Box␣2000, Tampere, Finland.
Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.
Epilepsy Behav. 2021 Feb;115:107691. doi: 10.1016/j.yebeh.2020.107691. Epub 2020 Dec 23.
The purpose of this cross-sectional retrospective study was to utilize EpiTrack to assess cognitive performance within the domain of attention and executive functions in patients with refractory epilepsy in consideration for treatment interventions either with antiepileptic drug (AED) changes and/or neuromodulation therapies. We also aimed to identify the relevant clinical and treatment factors possibly affecting EpiTrack performance.
The patient group consisted of 95 consecutive refractory epilepsy patients who were evaluated with EpiTrack. Based on their EpiTrack performance, the patients could be categorized as cognitively unimpaired, mildly, or severely impaired. The patients were also divided into three groups based on the planned treatment modification: AED group (n = 38) with only AED treatment, vagal nerve stimulation (VNS) group (n = 40) and deep-brain stimulation (DBS) group (n = 17). However, the effect of planned interventions was not the subject of this study. We retrospectively reviewed the medical records for detailed clinical characterization.
EpiTrack performance was severely impaired in 48 (50.5%), mildly impaired in 22 (23.2%) and unimpaired in 25 (26.3%) of the patients. The DBS group had significantly lower EpiTrack scores (mean (SD) and median, 25.5 (4.81) and 27.0, respectively) compared to the AED group (28.6 (6.2) and 30.0, respectively, p = 0.049). Sixty-three (66.3%) of the whole study population had more than 2 AEDs. When comparing EpiTrack scores between patient groups based on the number of AEDs administered, there was a trend toward better performance in EpiTrack with 2 AEDs as compared to 3-4 AEDs.
Deficits in attention and executive functions were frequent among patients with refractory epilepsy. Deficits were evident in all three treatment groups being most severe in the DBS group reflecting the patient selection. Furthermore, the effect of AED burden on executive functions was remarkable since two thirds of the patients had more than two AEDs and the deficits were more prominent among those with a higher AED burden. These results highlight the benefits of a feasible screening tool such as EpiTrack for assessing attention and executive functions when optimizing the treatment effects of neurostimulation therapies on cognition, and when evaluating the impacts of the AED burden.
本横断面回顾性研究旨在利用 EpiTrack 评估难治性癫痫患者注意力和执行功能领域的认知表现,以便考虑进行抗癫痫药物 (AED) 治疗干预改变和/或神经调节治疗。我们还旨在确定可能影响 EpiTrack 表现的相关临床和治疗因素。
患者组由 95 例连续接受 EpiTrack 评估的难治性癫痫患者组成。根据他们的 EpiTrack 表现,患者可以分为认知功能正常、轻度受损或严重受损。患者还根据计划的治疗修改分为三组:仅接受 AED 治疗的 AED 组 (n=38)、迷走神经刺激 (VNS) 组 (n=40) 和深部脑刺激 (DBS) 组 (n=17)。然而,计划干预的效果不是本研究的主题。我们回顾性地审查了病历以进行详细的临床特征描述。
48 (50.5%)例患者 EpiTrack 表现严重受损,22 (23.2%)例患者轻度受损,25 (26.3%)例患者认知功能正常。DBS 组的 EpiTrack 评分明显低于 AED 组 (平均值 (SD) 和中位数分别为 25.5 (4.81) 和 27.0,p=0.049)。整个研究人群中有 63 (66.3%)例患者使用了超过 2 种 AED。当根据给予的 AED 数量比较患者组之间的 EpiTrack 评分时,与使用 3-4 种 AED 相比,使用 2 种 AED 的 EpiTrack 表现有改善趋势。
难治性癫痫患者中注意力和执行功能缺陷很常见。在所有三个治疗组中都存在缺陷,在 DBS 组中最为严重,反映了患者的选择。此外,AED 负担对执行功能的影响显著,因为三分之二的患者使用了两种以上的 AED,并且在 AED 负担较高的患者中,缺陷更为明显。这些结果强调了可行的筛选工具(如 EpiTrack)在优化神经刺激治疗对认知的治疗效果和评估 AED 负担的影响时评估注意力和执行功能的益处。